| Logo | Name | Σ | Employees |
|---|---|---|---|
 |  TRON-Mainz Science in Translation - We put inspiration into practice, finding viable solutions to complex challenges. Our mission is to turn scientific breakthroughs into progress for patients. TRON is a non-profit research institute that pursues new diagnostics and drugs for the treatment of cancer and other diseases with a high medical need. We aim to bridge the gap between fundamental science at universities and market-oriented research in the pharmaceutical industry. We turn innovative scientific concepts into treatments ready for clinical testing, thereby accelerating the translation of discoveries into new diagnostics and therapies for patients. We focus our transdisciplinary competencies in genomics … 122 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 195 |
 |  Century Therapeutics, Inc Harnessing the power of adult stem cells to develop curative therapies for cancer and autoimmune diseases Our genetically engineered, iPSC-derived cell products are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of … 100 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 167 |
 | OxSonics Therapeutics Tackling the toughest cancers. We’re OxSonics, a pioneering clinical-stage therapeutics company committed to developing a ground-breaking platform technology to make anti-cancer drugs smarter, act faster and, above all, work better. Our SonoTran® Platform has been designed to actively enhance the delivery of oncology drugs into solid tumours. SonoTran® is drug agnostic and requires no drug reformulation enabling its use with both existing and novel therapies. We have our own development programs as well as collaborations with Pharmaceutical and biotech companies to work to bring smarter, faster and better therapies to as many patient groups as possible. Drug Delivery, Oncology, Medical … 80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 14 |
 | Shorla Oncology At Shorla Oncology we develop and commercialize innovative oncology medicines for women’s and pediatric cancers. At Shorla Oncology we develop and commercialize innovative oncology drugs. We focus on indications where existing treatments are limited, in shortage or inadequate for the target population. Our products are the result of Shorla’s world class team encompassing thought leaders, clinicians, scientists and commercial strategists who have extensive experience in the area of drug development and commercialization of niche cancer treatments. Our growing portfolio will bring accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical … 33 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 8 | 50 |
 | AOA Dx Transforming Women’s Health with Breakthrough Cancer Diagnostics and AI AOA Dx is leading a revolutionary breakthrough in early-stage cancer detection for women, leveraging the transformative potential of AI and our proprietary biomarker technology. At the heart of this innovation is our GlycoLocate platform, a multi-omics approach powered by tumor marker gangliosides, lipids and proteins. This platform is setting a new gold standard in the quest for life-saving early cancer diagnostics. We are now advancing AKRIVIS GDTM, a cutting-edge liquid biopsy test designed specifically for the early detection of ovarian cancer. Medical Devices, Diagnostics, Prognostics, Biotechnology, Sales, Commercialization, Regulatory, Licensing, Quality, … 55 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 7 | 54 |
 | bit.bio The Cell Coding Company bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable … 62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 164 |
 | LIfT BioSciences World leaders in neutrophil immunotherapies to rejuvenate immune competence in solid tumours and beyond! LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media … 59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 19 |
 | iOnctura Developing precision small molecules to combat hard-to-treat tumors. iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families. Two therapeutic candidates have progressed into mid-stage clinical development: roginolisib is the first allosteric modulator of PI3Kδ and cambritaxestat is the only autotaxin inhibitor in clinical development to treat cancer. oncology, drug development, and clinical development 81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 9 | 33 |
 | AstriVax Therapeutics Pioneering immune interventions to treat chronic disease AstriVax Therapeutics is a European based, clinical-stage biopharmaceutical company, founded in 2022, that is pioneering immune interventions to treat chronic disease. The company has two prototype prophylactic assets in clinical phase and is developing its therapeutic assets to treat chronic HBV and clear high-risk HPV. AstriVax has a novel DNA-launched viral vector immunotherapy platform, Launch-iT, that is designed to create an inherent adjuvant effect to the target antigens, eliciting durable polyfunctional CD8+ and CD4+ T cell responses and robust humoral immunity. Through Launch-iT, the company has the potential to develop best-in-class immunotherapy treatments. 85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 36 |
 | Oniria Therapeutics A shift in cancer treatment methodology makes a world of difference. A shift in cancer treatment methodology makes a world of difference. Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA). Oniria Therapeutics is a biotech company focused on the development of first-in-class drugs in the field of precision oncology. It develops therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product allosterically activates TET2, a master epigenetic enzyme. Biotechnology, cancer, cell … 57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 17 |
 | Genenta Science (Nasdaq: GNTA) Genenta is a clinical stage immuno-oncology company Genenta (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a proprietary hematopoietic stem cells therapy for the treatment of a variety of solid tumor cancers. Genenta's first in class product candidate is TemferonTM, which is designed to allow the expression of immune-therapeutic payloads within the tumor microenvironment by bone marrow derived myeloid cells and enable a durable and targeted response. Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter, which suggests the potential reprogramming of the tumor microenvironment and inhibiting of myeloid … 10 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 7 | 24 |
 | Oncimmune - An Alden Scientific Company We understand disease through the lens of the immune system for more effective, safer treatments & better diagnosis. Oncimmune has developed the most advanced and comprehensive analytical platform for the discovery of Antibody / Autoantibody Biomarker Signatures. ImmunoINSIGHTSTM, the best-in-class biomarker discovery engine, provides access to the B cell repertoire and a pivotal class of biomarkers. With one of the world’s largest antigen libraries covering 9000+ human antigens and multi-species variants, we profile antibodies from various biologic samples in very low volume (50 μl). Developed and curated by immunologists and a team of bioinformaticians, we offer high content biological insights … 74 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 8 | 40 |
 | LiberaBio Addressing "undruggable" oncology targets by delivering whole antibodies inside the tumor and metastatic cells. Libera Bio is a preclinical stage biotech that develops new oncology treatments based on the proprietary MPN technology. This nanotechnology actively targets tumor and metastatic cells and delivers small and large molecules to on-surface, transmembrane or intracellular targets. The company is creating new treatments by delivering novel antibodies targeting intracellular oncoproteins. << Fraud Alert for Potential Candidates >> At Libera Bio, your personal information and online safety are our top priorities. • Candidates should apply exclusively through our official webpage at https://www.liberabio.com/contact/ or rrhh@liberabio.com. • If … 14 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 10 |
 | Phialogics - The native biologics platform company Phialogics state of the art platform transforms native proteins into powerful therapeutics. Phialogics is developing a pipeline of bi-functional, bi-specific and multi-specific molecules to treat autoimmune diseases. Our unique First-in-Class immunomodulatory approach has a proof of concept in several translational in vivo models as well as in patient-derived materials ex vivo. 60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 5 |
 | Mosaic TX Resolving cancer's complexity through the power of targeted drug combinations ABOUT US Mosaic Therapeutics is an oncology therapeutics company delivering precision medicines for patient groups with few targeted treatment options today. The company’s main mission is to tackle cancers with substantial unmet need by reinventing the traditional approach to target and drug discovery - leveraging our differentiated dual technology platform to advance novel combination therapies. Born out of pioneering research at the Wellcome Sanger Institute in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of fine-tuning and development, Mosaic has active … 158 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 26 |
 | Aurealis Therapeutics Multi-target cell and gene therapies for unmet medical needs. Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammation. After successfully completing our Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients with our lead clinical product AUP-16, our DFU Phase 2 study is ongoing in Italy, Germany and Poland. Venous Ulcers and other ulcers will follow. In Oncology, … 8 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 18 |
 | Mnemo Therapeutics Empower the body, cure the disease Mnemo Therapeutics is a Paris-based biotechnology company driven to create powerful immunotherapies by improving the body’s ability to detect and eradicate cancer. The paucity of actionable cancer-specific targets creates significant challenges in the field of immuno-oncology. To address this, Mnemo has developed a combination of in-silico and wet-lab pipelines to uncover new tumour-specific targets (called E-antigens) derived from the unexploited dark genome, and to develop multiple therapeutic modalities (i.e. cell therapy, TCE, ADC, vaccine) targeting these E-antigens. Mnemo is currently pursuing several discovery campaigns for E-antigens, with a plan to develop its proprietary tumour-specific … 11 similar entities Type: Startup Activities: biotech Technologies: Synthetic Biology | 6 | 25 |
 | RaySearch Laboratories Advancing Cancer Treatment ADVANCING CANCER TREATMENT RaySearch is advancing cancer treatment through pioneering software. Software has unlimited potential, and we believe it is now the driving force for innovation in oncology. Medical science never stands still, and neither does RaySearch. We work in close cooperation with leading cancer centers to bring scientific advancements faster to the clinical world. Today, our solutions support thousands of clinics worldwide in the fight against cancer. And this is just the beginning. software, radiation therapy, optimization, usability engineering, cancer care, Oncology Information Systems, cancer treatment, and Treatment planning systems 9 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: SaaS | 3 | 414 |
 | Immatics The Global Leader in Precision Targeting of PRAME Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. Read more about Immatics on our homepage: https://immatics.com/ … 23 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 591 |
 | TOLREMO therapeutics Stopping non-genetic cancer drug resistance as it emerges TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the response rates and durability of established treatments. By stopping cancer drug resistance as it emerges, we aim to surmount a universal challenge for current and future targeted therapies for lasting patient benefit. Drug Discovery, Drug Development, Cancer Drug … 20 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 16 |
 | Akamis Bio Harnessing the Power of Tumor Gene Therapy to Turn the Tide in the Battle Against Cancer Headquartered in Cambridge, Massachusetts, Akamis Bio is a clinical-stage oncology company developing systemically administered immunotherapies to treat solid tumors, initially in patients with locally advanced rectal cancer (LARC). Its proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform is designed to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors, with its lead clinical-stage program, NG-350A, driving intratumoral expression of a CD40 agonist monoclonal antibody. To learn more, please visit www.akamisbio.com. Immuno-oncology and Re-programming the Tumor Microenvironment 8 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 5 | 37 |
 | Immunophotonics, Inc. Interventional Immuno-Oncology Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their … 68 similar entities Type: Startup Activities: biotech deeptech legaltech Technologies: Synthetic Biology | 3 | 19 |
 | Nodus Oncology Developing next generation DDR targeting therapies Nodus oncology is developing first and best-in-class molecules inhibiting novel targets within the DNA damage response and replication stress response. Supported by most recent scientific advances, we are developing the next wave of cancer therapeutics in the DNA damage response (DDR) area. Founded by Cumulus Oncology and in partnership with the Lead discovery Center, Nodus Oncology is developing an innovative portfolio focused on synthetic lethality and collateral vulnerabilities in molecularly defined cancer patient populations Oncology 22 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 4 |
 | Valo Therapeutics Ltd Reinventing Cancer Immunotherapy Valo Therapeutics (ValoTx) is a developer of novel immunotherapies in cancer and infectious disease. Our unique approach to immunotherapy, based on oncolytic viruses and viral vectors combined with disease-specific peptides, delivers highly adaptable and immunogenic therapeutic vaccination platforms. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of immunotherapy experts, who together with the founding scientists have the necessary expertise to take its patented technology through clinical development and make it available to patients. The management team has a proven track record of developing successful companies from a laboratory idea … 83 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 19 |
 | Cure51 We want every patient to become a Cancer Survivor. Cure 51 is a TechBio aiming at creating the first ever worldwide database of Cancer Survivors. The company was co-created with leading oncology centres and has already identified more than 1500 survivors in 42 countries across all continents. The company has developed its own data collection and discovery platform as well as a dedicated Central Lab to proceed to a multiomic sequencing of the survivors’ samples. Through this approach, Cure51 will identify robust therapeutic targets, validated by its scientific community, in order to develop novel drugs to cure Cancer. The focus … Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 12 | 49 |
 | PharmEnable Therapeutics Harnessing the power of chemical novelty, diversity and 3-dimensionality to develop innovative small molecule drugs PharmEnable is a biopharmaceutical company utilizing AI to discover effective small-molecule medicines for disease targets that are inaccessible to antibodies. With our proprietary AI-enabled drug discovery platform, chemSEEK, we explore new chemical spaces and discover novel small molecules with antibody-like specificity and selectivity. We are developing a pipeline of wholly owned therapeutics with initial focus on oncology and neurology. We also engage in drug discovery partnerships across a range of disease areas where accessing the target poses a significant challenge. PharmEnable is based in Cambridge, … 110 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 17 |
 | NeoPhore Ltd Discovering drugs that create neoantigens NeoPhore, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Generation of cancer neoantigens in tumours can be exploited by the patients’ immune system to overcome natural defence mechanisms in cancer. The Company’s approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. Using these insights, NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore was spun-out of the University of Turin and PhoreMost … 50 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 22 |
 | Concr Solving data to enable precision therapy for all Concr is a techbio company providing predictive modelling solutions to enhance confidence and foresight about therapeutic efficacy of existing and emerging cancer drugs. By accurately predicting response for individual patients and cohorts, we enable more efficacious and informative trials, thereby improving probability of success of novel cancer therapeutics. Our Farr-Sight® platform, built on decades of astrophysics research, models diverse data interactions to simulate human disease biology, enabling accurate predictions with minimal data. This is especially valuable in early-stage trials and rare cancers. Validated through collaborations with Roche, Step Pharma, The Institute of … 55 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. - Machine Learning A.I. | 9 | 9 |
 | Curve Therapeutics Revolutionary intracellular screening platform enables a new generation of first-in-class drugs. Our mission is to transform the discovery of first-in-class small molecule therapeutics by broadening the landscape of disease targets that can be drugged. Our Microcycle® platform enables direct screening for biologically active hits inside mammalian cells and creates a toolkit for hit-to-lead programmes. We are deploying our innovative platform to build a pipeline of first-in-class small molecules to address high priority, therapeutically relevant cancer targets. 58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 37 |
 | Lantern Pharma Inc. (Nasdaq: LTRN) Leveraging Artificial Intelligence to Rescue and Develop Cancer Therapies Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials. Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent combinations. Our approach which leverages our RADR … 59 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 1 | 29 |
 |  ElyssaMed SAS ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant. This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction. Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 2 |
 | Rosetta Omics Unlocking the road to precision medicine by tumor characterization via high resolution proteomic profiling. Worldwide, there are more than 20 million new cases of cancer each year. First-line therapies are not always the most effective and there is a strong need to move towards personalized medicine by offering the patients the best treatment as quickly as possible. This will help in increasing the chance or cure. Therefore, there is a need to improve the prediction of the response to treatments to be able to save patient’s lives and reduce the cost of expensive inefficient treatments. Our goal is to unlock … Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology A.I. - Machine Learning | 25 | 10 |
 | Pharvaris Pioneering science for patient choice Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically … 69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 124 |
 | Silence Therapeutics plc Precision Engineered Medicines to Silence Diseases Our 20-plus years of RNAi experience together with our validated mRNAi GOLDTM platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients … 48 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 102 |
 | Pear Bio Patient-centered cancer precision medicine Pear Bio analyzes patient tumor samples and data with a proprietary computational biology platform to deconvolute complex cancer biology and drive patient-centric functional precision medicine and drug discovery. Our ultimate goal is to optimally allocate approved treatments to cancer patients who will benefit from them, while creating novel therapies that are purpose-designed for patients who don't respond to available treatments. The platform uses microphysiological systems and 3D computer vision to measure cancer progression over time. Pear Bio cultures patient tumor samples with matched blood into 3D immune-microtumors to test potential treatment options and combinations ex vivo. … 26 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 3 | 28 |
 | HOOKIPA Pharma Inc. Supercharging Immunotherapy At HOOKIPA, we envision a world in which cancers and infectious diseases can be chronically managed or eradicated. HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company advancing the field of immunotherapy through the development of new immunotherapies based on our proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. Our pipeline includes wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV … 20 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 4 | 53 |
 | DIAG2TEC Preclinical CRO in Hematological Cancers Diag2Tec is an expert preclinical CRO devoted to hematological cancers, especially Multiple Myeloma (MM). We focused on in vitro Drug Testing in Human Hematological Cancer derived Cell Lines and Primary Cells from patients with various Hematologic Malignancies (Multiple Myeloma, Diffuse Large B Cells Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Mantle cell Lymphoma, Chronic Lymphoid Leukemia...). With our 2 platforms : Drug Testing Services and ChimioFx, our mission is to provide efficient treatment solutions for patients suffering from Hematological Malignancies with Precision Medicine approaches. We support biotech and phamaceutical companies to focus their drug development on … 26 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 9 |
 |  Cellestia Biotech Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD) Biopharma, Oncology, Precision Medicine, Small Molecules, Targeted Therapy, Biotech, Cancer Therapy, Transcription Factors, Autoimmune Disorders, and Inflammatory Disorders 150 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 8 |
 | Eisbach Bio GmbH Targeting synthetic lethality in cancer Eisbach Bio is an innovative start-up in biotechnology founded in 2019 as a spin-out of the Biomedical Center Munich. We are developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes. Eisbach will beat cancer at its own game. 58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 11 |
 | NEOGAP Therapeutics AB Science for cure. NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden. Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy. Biopharmaceutical company, Immunotherapy, and Immuno-oncology 61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 30 |
 | Asgard Therapeutics Swedish biotech company exploring reprogramming as the next leap forward in cancer immunotherapy Asgard Therapeutics is a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy. The company builds on ground-breaking and proprietary reprogramming technologies to develop gene therapy products designed to set in motion efficient and personalized immune responses. Backed by top investors, Asgard Therapeutics aims to establish a pipeline of off-the shelf cancer immunotherapies that trigger personalized anti-cancer immune responses for the benefit of cancer patients in need. Cell Reprogramming, Cancer Immunotherapy, and Dendritic cells 144 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 27 |
 | Orakl Oncology Biology x AI-powered drug development platform to transform precision oncology. Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster. 61 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics Synthetic Biology | 2 | 22 |
 | TheraPPI Bioscience Targeting protein interactions for health Founded in 2023, TheraPPI Bioscience is a biotechnology company whose science originates from the CRCL (Centre de Recherche de Cancérologie de Lyon, France). We modify protein interactions to offer treatments where current therapies fail. Our approach represents a paradigm shift in tackling cancer resistance and non-curable rare diseases protein-protein interaction, PPI, small molecule, therapeutics, oncology, and rare disease 76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 5 |
 | IMD-Pharma SAS Rebalancing the immune system, resolving inflammation. Drug candidates from our molecular platforms normalize the immune system by downregulating pro-inflammatory immune response and upregulating regulatory immune response. IMD-Pharma S.A.S is a french biotechnology company conducting research and development of innovative drug candidates for immune-related inflammatory diseases. Founded in 2016, IMD-Pharma is a company from the Laboratoire de Chimie de Coordination (CNRS) and the Centre de Physiopathologie de Toulouse Purpan (INSERM/CNRS/Université Toulouse III). immuno-modulation, anti-inflammatory drugs, chronic inflammatory diseases, Multiple Sclerosis, Rheumatoid Arthritis, dendrimers, monocyte rehabilitation, and psoriasis 46 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 6 |
 | Blue Bees Therapeutics Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug 176 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 8 | 9 |
 | Smart Immune Pioneering thymus-empowered T-cell platform to fight cancer and infection Smart Immune is a clinical-stage French biotechnology company developing ProTcell, a thymus-empowered T cell progenitor platform to fully and rapidly re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies. The company aims to radically improve outcomes for patients in hematology and immune-oncology. Smart Immune has ongoing collaborations with leading institutions in the US and Europe. SMART101 is in Phase I/II clinical trials in cancer patients with AML and ALL, in SCID in the EU and the US. Smart Immune is also developing therapies using gene-modified T … 51 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 27 | 32 |
 | ADC Therapeutics Innovating Science. Inspiring Hope. ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. We are a pioneer in the ADC field with specialized capabilities unique to ADCs from clinical to manufacturing and commercialization with a proven track record that includes an approved and marketed product. Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after … 8 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 320 |
 | Kezar Life Sciences Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be … 153 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 59 |
 | OREGA Biotech Discovery of novel immune checkpoint inhibitors for cancer immunotherapy OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. The company was incepted in 2010 and is managed by Jeremy Bastid, CEO and Gilles Alberici, President. The science at OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our in vivo screening approach aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate (2016) Pharma and then partnered … 67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 7 |
 | Inoviem Scientific Creative Technologies for Efficient Therapeutics, Precision medicine Inoviem Scientific is a private Bioanalytical company which delivers enabling information to secure drug discovery programs and to take informed decision by closing the gap between preclinical and clinical development. We reconcile translational pharmacology and human physiology by using fresh patient material from the target cohort, embracing the complexity of human diseases. Inoviem's enabling technologies are working in pathological conditions to get the treatment in development to the right patient. Our indication-agnostic access to patients combined with innovative label-free platforms deliver Target identification and validation, targets & Mode of Action deconvolution, patient stratification, … 82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 8 |
 | Mestag Therapeutics New therapies for inflammatory disease and cancer by targeting fibroblast immunology Mestag focuses on fibroblast-immune interactions to develop innovative new treatments for inflammatory disease and cancer. Through our unique understanding of fibroblast immunology, we are advancing a pipeline of first-in-class antibody programs and targets for new treatments. Backed by committed leading global investors, world-class founders and a highly experienced leadership team, Mestag offers an exciting, diverse and balanced place to work, with competitive benefits, generous vacation time and the room to grow and develop your career. biotechnology, fibroblasts, oncology, immuno oncology, inflammatory disease, and datascience 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 55 |
 | CRISPR Therapeutics Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients … 59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 12 | 392 |
 | ImmuneBridge Amplifying nature’s innate intelligence to fight cancer ImmuneBridge is developing allogeneic immunotherapies for cancer. Our core technology drives the expansion of cord blood derived immune stem cells and establishes a novel, flexible, consistent and abundant cellular source for immunotherapies. We are currently pursuing natural killer cell products for hematological malignancies. Next we will use the unique advantages of our cellular source to tackle solid tumors. Platform ImmuneBridge is creating a platform of scalable allogeneic immune cell therapies from cord blood. Our proprietary technology, including a novel small molecule, expands cord blood HSPCs over 100,000-fold while maintaining full immune multipotency, with … 14 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 19 |
 | AAX Biotech AB Leveraging science and innovation to accelerate the development of next-generation antibody therapeutics. AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, SeqitopeTM and Opti-mAbTM, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs … 75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 8 |
 | Resolution Therapeutics Pioneering Macrophage Cell Therapy for Transformative Outcomes in Inflammatory Organ Diseases Resolution Therapeutics is a biotechnology company developing macrophage cell therapy to treat inflammatory organ disease. The company was founded following a productive collaboration between Edinburgh’s Centre for Regenerative Medicine, the Scottish National Blood Transfusion Service, and Syncona Investment Management Limited. The company is based in the Centre for Regenerative Medicine on the Edinburgh Royal Infirmary Campus, and is backed by Syncona. Our initial focus is in chronic liver disease. It is the only chronic disease still on the rise in western countries, and affects millions of people worldwide. Unfortunately, … 27 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 74 |
 | VitroScan Predicting treatment outcome VitroScan is a Dutch biotech company founded in 2016 and based at the Leiden Bio Science Park. We develop certified predictive ex vivo 3D tumor testing services for reliable treatment response prediction for the clinic and to improve patient stratification for clinical trials. Our proprietary technology provides highly reproducible drug testing in the native tumor microenvironment (TME). VitroScan’s clinical trial program is performed in collaboration with expert clinicians from leading oncology centers. In these trials patient specific ex vivo tumor sensitivity to chemo-, targeted, or immunotherapy is correlated to clinical outcomes. We are dedicated to delivering predictive … 29 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 8 |
 | Genewity B.V. Genewity is a pioneering biotech start-up focused on advanced thymus-driven therapies for immune reconstitution. Supported by the extensive business expertise of our management and advisors, we are at the forefront of developing and commercialising breakthrough therapies. With over 150 years of combined experience in immunology and gene therapy, our team is uniquely positioned to drive advancements in the field. 273 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 17 |
 | Apmonia Therapeutics Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Our innovative technological approach is to target tumors overexpressing matricellular protein thrombospondin-1 (TSP-1). Our long-term vision is to develop personalized immunotherapy approaches combining a proprietary therapeutic peptide targeting TSP-1 (namely TAX2 peptide) and a companion diagnostic kit, which may enable patient stratification for TAX2 therapy eligibility based on the monitoring of circulating TSP-1. immunologie and oncologie 28 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 39 | 18 |
 | Predicta Biosciences A precision oncology company integrating multiomics to develop innovative diagnostic and therapeutic products. Predicta Biosciences is a precision oncology company integrating cutting edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Predicta's diagnostic product portfolio removes the burden of bone-marrow biopsies, through small blood-based samples, and enables best-in-class treatment decision-making for immunotherapies. Utilizing the data from the diagnostic platform, Predicta has an in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development. 30 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 6 |
 | Cell BioEngines, Inc ‘Off-the-Shelf’ Curative Cell Therapies About Us: Cell BioEngines, Inc., founded in Dec 2022, is a clinical-stage biotech company focused on developing allogeneic 'off-the-shelf' stem cell and its derived therapies as ‘drugs’ for human disease treatment. The company utilizes a ‘plug-and-play’ proprietary platform technology that transforms universal ‘non-gene-modified’ donor blood stem cells from umbilical cord, to produce high-quality, pure and potent, multiple clinical grade cells at scale. This innovative method aims to make stem cells and its derived therapies more accessible and efficient. Its lead product is currently in Phase 1 trials for the treatment of hematopoetiic neoplasms not curable with … 63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 2 |
 | Sarcura Powering New Possibles in Cell Therapy Manufacturing Cell therapy has transformed cancer treatment, yet the hurdles of manufacturing patient-derived cell therapies remain a formidable challenge for the industry. Quality and scalability problems lead to high therapeutic costs and limit access to those life-saving treatments. By harnessing the power of cutting-edge semiconductor technologies, including silicon photonics seamlessly integrated into microfluidic cartridges, Sarcura is orchestrating a transformative shift. Central to Sarcura's mission is the creation of fully automated manufacturing systems endowed with real-time process and product control. This pioneering platform promises to usher in a new era of cost-effective and secure cell … 18 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 25 |
 | Cytovation Creating transformative medicines for patients with cancer Cytovation is a clinical stage immuno-oncology biotech developing first-in-class immunotherapies. CY-101, its lead asset, is a synthetic peptide engineered to selectively target tumor cells. CY-101 has a unique dual MoA applicable across solid tumors: (1) direct tumor-specific membrane lysis and in-situ vaccination, combined with (2) immune activation through inhibition of the β-catenin pathway. Building on strong FIH clinical data, Cytovation is advancing CY-101 to POC/pivotal clinical development with a focus on b-catenin-driven cancers. Biotech, Oncology, and Immuno-oncology 33 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 12 |
 | Serendip innovations Delivering Value Through the Power of Plants Serendip Innovations is a preclinical-stage biotechnology company developing a cutting-edge nanoparticulate delivery platform for active ingredients. We offer co-development partnerships and technology licensing opportunities for applications such as therapeutic and prophylactic vaccines, as well as precision medicine. What sets us apart is the high modularity of our platform, enabling the custom design of a new generation of targeted therapeutics. As a first application, Serendip is addressing the challenges of therapeutic cancer vaccines by transforming its platform into a high-performance immunization system. This system enhances the presentation of tumor antigens and elicits strong anti-tumor … Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 17 | 11 |
 | CenExel A leading nationwide clinical research site network pursing life-changing therapies committed to better patient outcomes CenExel is a leading integrated, wholly owned, nationwide clinical research site network comprised of 18 Centers of Excellence in major metropolitan areas across the U. S. With 40+ years of experience, our Centers of Excellence deliver deep scientific expertise, premium data, operational efficiencies, and exceptional patient engagement to drive successful complex clinical trial outcomes. The world's most results-driven Pharma, Biotech, and Clinical Research Organizations trust our strategic approach and benefit from our collaboration and unified sites’ commitment to real world solutions. Rely on us to … 82 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 11 | 733 |
 | Surface Oncology Inc. #lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2022,2021 Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies … Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 9 |
 | GenEdit Delivering the potential of genetic medicines GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible. The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease. We are focusing our research on … 39 similar entities Type: Startup Activities: biotech deeptech nanotech Technologies: Synthetic Biology | 0 | 55 |
 | Forma Therapeutics Dedicated to transforming the lives of patients with rare hematologic diseases and cancers. Forma Therapeutics (Nasdaq: FMTX) is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. We aim to create futures for patients, their families … 75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 205 |
 | Pyxis Oncology Charting a course to therapeutics for difficult-to-treat cancer. Pyxis Oncology is transforming the lives of patients with cancer by advancing our differentiated portfolio of biologics that specifically target tumor cells and overcome immune suppression. We believe that antibody-drug conjugates (ADCs) and immunotherapies have the potential to address difficult-to-treat cancers and improve patient outcomes. Immuno-oncology and oncology 31 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 3 | 60 |
 | Ikena Oncology Patient-directed oncology therapies across pathways relevant in tumor and immune cells Ikena is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of wholly owned and partnered programs focused on genetically defined or biomarker-driven cancers, which … 125 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 5 | 22 |
 | Altevax Biotech Altevax is developing a disruptive immunotherapy technology against cancer Altevax is developing a powerful pioneering immunotherapy technology against cancer. Its patented melanin-based technology has been proven in pre-clinical trials to boost an antigen-specific immune response with Cytotoxic T-lymphocytes (CD8+ Killer T cells), the body’s most powerful defenders. The Altevax immunotherapy technology works with a wide range of peptides. The Altevax technology is complementary to other anti-cancer immune technologies, such as anti PD1s. Altevax is developing an immunotherapy against glioblastoma, currently in advanced pre-clinical development, with Phase 1/2a expected in early 2024. Altevax's partnership with Assistance Publique Hôpitaux de Paris and … 10 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 11 | 6 |
 | JURA Bio, Inc. Building the future of AI drug development with the data that matters. CAR-T is for more than just oncology. Using the full potential of gene editing, we are creating a therapeutic platform for cell based therapies that are not just disease modifying: they are curative and definitive. Cell-based Therapies and Machine Learning 115 similar entities Type: Startup Activities: biotech healthtech deeptech Technologies: Synthetic Biology SaaS A.I. Generative A.I. | 0 | 15 |
 | CARLA Biotherapeutics First In Class Adoptive Cell Therapies to Cure Patients Carla Biotherapeutics is a Biotech company developing first-in-class adoptive cell therapies tailored to treat diseases with high unmet medical need with a first focus on aggressive life-threatening cancer. Carla Biotherapeutics is founded by a team of seasoned clinicians, cell therapy scientists and biotech professional in Besançon, France with access to a world-class and unique cell-therapy platform. Carla Biotherapeutics’ ambition is to build and develop a pipeline of immunotherapies based on a fully integrated cell therapy platform to discover ena develop adoptive cell therapies tailored to each indication. 37 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 11 | 2 |
 | Odimma Therapeutics Empowering Personalized Immunotherapy to Treat Cancer Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy. Immunotherapy has revolutionized the treatment of many advanced cancers. Despite this amazing achievement, significant clinical benefits are still limited to 10 to 30% of patients. Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to amplify the efficacy of current therapies, improving lives and making each patient unique. By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has … 31 similar entities Type: Startup Activities: manufacturing deeptech biotech Technologies: Synthetic Biology | 12 | 6 |
 | SPIMA Therapeutics Unlocking New Immunotherapy Paths with Smart Peptides SPIMA Therapeutics emerges as a spin-off from the University of Montpellier, France, uniting experts in cutting-edge peptide chemistry and inflammation biology. SPIMA focuses on developing innovative peptide-based immunotherapies for challenging targets, particularly protein-protein interactions. Our lead program is a Stapled Peptide targeting the Myddosome complex. This innovative approach holds immense promise for revolutionizing treatments in inflammatory and oncological diseases, offering hope where it's needed most. SPIMA Therapeutics is part of the nexus of Landmark Bioventures. Join us in shaping the future of medicine, where discovery meets dedication. Immunothery 22 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 3 |
 | Seekyo Therapeutics Tumor Activated Therapy: targeting Tumor Micro-Environment functional proteins to induce tumor self-destruction The heterogeneity of cancer cells constitutes a strong limitation for the treatment of solid cancers like pancreas and Breast TNBC. Shifting to a new paradigm, Seekyo, a pre-clinical biotech Co. overpowers this challenge by targeting specific functional proteins selectively produced within the Tumor Micro-Environment (TME). Seekyo’s lead compound SKY01 induces a selective tumor self-destruction: • Efficacy and safety validated in small and large animals (e.g. Dogs). • Unprecedented antitumor efficacy vs. Standards of Care • Efficient in several tumors (Pancreas, Triple Negative Breast Cancer, lung, colorectal...) • Low … 46 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 7 |
 | Spur Therapeutics Toward the next generation of gene therapy. Spur Therapeutics (formerly Freeline Therapeutics) is a clinical-stage biotechnology company focused on developing life-changing therapies for debilitating chronic conditions. By optimizing every component of our product candidates, we are improving genetic expression and targeted delivery to realize outsized clinical results. Building on the successes of our two potential first-in-class therapies for Gaucher disease and adrenomyeloneuropathy (AMN), we’re moving from rare diseases toward more widespread conditions, including forms of Parkinson’s and dementia, and even certain cardiovascular diseases. Expanding our impact, and pushing forward to new frontiers of genetic medicine. Toward life-changing therapies, and brighter … 87 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 329 |
 | FairJourney Biologics Your trusted partner for innovative, end-to-end antibody services At FairJourney Biologics, we specialize in cutting-edge antibody discovery and development, offering end-to-end solutions that fast-track your research. With over a decade of expertise, our innovative technologies and seasoned team have successfully advanced 14 antibodies to clinical stages. Our adaptable partnership model empowers projects of any scale, fostering collaboration and breakthrough innovation. Whether you're in early-stage research or development, we deliver tailored, high-quality antibodies designed to meet your specific needs. Join us in revolutionizing therapeutic discovery and making lasting impacts on global healthcare. Monoclonal antibodies, Antibody humanization, Antibody production, Antibody affinity maturation, … 73 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 289 |
 | Apollomics We are a biopharmaceutical company committed to the discovery and development of mono- and combination cancer therapies. Apollomics is an innovative biotechnology company committed to the discovery and development of oncology combination therapies. With operations in both the U.S. and China, we believe we are well positioned to unlock synergies by leveraging the strengths of partnerships with other biotechnology companies in the East and the West. Since our founding in 2015, under the leadership of our experienced management team with in-depth knowledge and expertise of the evolving cancer treatment landscape, we have built a pipeline of ten (10) drug candidates … 12 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 25 |
 | Precigen Precigen (Nasdaq: PGEN) is a biopharmaceutical company advancing the next generation of gene and cell therapies. Precigen: Advancing Medicine with PrecisionTM Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and … 59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 133 |
 | ALPIONER Therapeutics Building a pipeline of immuno-therapies to fight against cancer and multiresistant pathogens ALPIONER Therapeutics is a biotech company developing new generation of immunotherapies against cancer and multi-resistant pathogens. Its aT3-plaform is leveraging a bacterial secretion system to inject high quantity of peptides or functional proteins, into the cytosol of the host cell. ALP-102 is a first-in-class vaccine candidate targeting Pa infections while ALP-201-neo is neoantigen-based personnalized cancer vaccine. 67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 18 | 2 |
 | Enterome Delivering the promise of immunotherapy Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body. The company is currently developing a pipeline of drug candidates consisting of OncoMimicsTM peptide-based immunotherapies for the treatment of cancer. EO2463 is in a Phase 2 clinical trial for indolent non-Hodgkin lymphoma, demonstrating a benign … 61 similar entities Tags: FrenchTech2030 Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology | 15 | 42 |
 | Medannex Ltd Award-winning Scottish biopharmaceutical company, advancing the treatment of cancers and autoimmune diseases. Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1. Our goal is to create a first-in-class therapy to improve the lives of people impacted by cancers and autoimmune diseases. Following a recent Series B fundraise, and supported by both the Scottish Investment Bank and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology. Antibody development, Innovation, Biotechnology, T cell modulation, Skills development, Autoimmune diseases, Inflammation, Lupus, SLE, Collaboration, … 74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 12 |
 | Ethris Clinical stage biotech company focused on development of disruptive mRNA therapeutics for severe respiratory diseases Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners. Biotechnology, mRNA, LNPs, Vaccines, Therapeutics, Formulation, and Manufacturing 71 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 47 |
 | Leman Biotech Leman Biotech, a spin-off company of EPFL, aims at developing and commercializing new metabolic cancer immunotherapies Leman Biotech is a clinical-stage cancer immunotherapy company co-founded by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and XtalPi, a leader in AI-driven drug research and development. The company integrates innovative metabolic reprogramming technology with a cutting-edge AI drug discovery platform to develop next-generation cancer immunotherapies. Leman Biotech's Metabolic Reprogramming Technology (Meta 10) represents an innovative approach to combating T-cell exhaustion. Preclinical studies have demonstrated its ability to activate oxidative phosphorylation metabolism in terminally exhausted T cells, restoring … Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 2 |
 | Osivax Pioneering A New Class of Universal Vaccines Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company … 54 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 25 | 57 |
 | INOVACTIS Versatile immunotherapy for personalized cancer medicine Inovactis develops an innovative treatment against cancer at the border between several ongoing revolutions: individualized medicine, immunotherapy and synthetic biology. personalized immunotherapy and medicine 98 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 1 |
 | Domain Therapeutics #biopharma #biotech #drugdiscovery #GPCR #Immunooncology #inflammation Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and … 24 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 25 | 80 |
 | Valerio Therapeutics Valerio is a clinical-stage biotechnology company developing novel oncology drugs targeting tumor DNA-binding functions. Valerio Therapeutics is a clinical-stage biotechnology company based in France and the US that develops new drugs by targeting tumor DNA functions through unique mechanisms of action in the field of DNA Damage Response (DDR). DDR consists of a network of cellular pathways that detect, report and repair DNA damage. Applied to oncology, this new field of research aims to weaken or block the ability of tumor cells to repair damage to their DNA, either naturally or under the effect of cytotoxic treatments. Focusing exclusively on … 25 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 1 | 48 |
 | Relation Discovering the relationships at the heart of biology to cure disease. We are an end-to-end biotech developing transformational medicines, with technology at our core. Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure. Medicines born from high-resolution biology, machine learning and clinical insights. Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select … 77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 17 | 96 |
 | Calluna Pharma Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source. Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases. 46 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 21 |
 | Scancell Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. We have developed a pipeline of ‘off-the-shelf’ vaccines which induce immune responses and highly tumour specific monoclonal antibodies that redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and … Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology | 0 | 59 |
 | Infinitopes Preventing deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival. 293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 5 | 35 |
 | EsoBiotec We Empower Cells In Vivo to Fight Diseases. EsoBiotec is a biotechnology company developing innovative therapeutics to fight cancer. Our mission is to empower the human body to tackle cancer by bringing in vivo engineering of cells to patients. We aim to develop cost-effective and off-the-shelf therapeutics and providing state-of-the-art cell therapies to maximise accessibility. Our disruptive approach holds the potential to transform the current standard of cell and gene therapies for cancer treatment. Gene therapy, Biotechnology, Oncology, Cell therapy, Cancer, in vivo engineering, virology, and Immunology 77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 15 |
 | Hemispherian AS Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Our mission is to develop a new drug to treat Glioblastoma Multiforme. We aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients. cancer treatments, GBM treatments, and therapeutics 58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 10 |
 | ALKemist Bio Next generation cell therapies for ALK-positive cancer patients At ALKemist Bio we are developing TCR-T cells that possess the ability to specifically target ALK antigens found on ALK-positive cancer cells, primarily focusing on non-small cell lung cancer patients. By harnessing the power of the immune system and engineering T cells to precisely recognize and combat these cancerous cells, we aim to pave the way for more effective treatments aiming at improving the standard of care. biotech, immunooncology, oncology, alkpositive, celltherapy, TCR, and ALK 118 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 5 |
 | LinKinVax LinKinVax aims at creating a universal, safe, enduring, vaccines platform against multiple pathogens. We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a unique "DC targeting" platform covering infectious desaeses and oncology. 158 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 11 | 2 |
 | Orakl Oncology Biology x AI-powered drug development platform to transform precision oncology. Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster. 61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology Data Analytics | 32 | 22 |
 | OSE Immunotherapeutics Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors. • Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. • OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. • FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase … 57 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 27 | 1 |
 | IMODI Cancer Building a sustainable sector and accelerate the discovery of new treatments tailored to each patient. French consortium to develop new experimental models of cancer in 9 cancer pathologies of interest (Lung, Pancreas, Breast, Liver, Ovary...) 3 major R&D axes: - Developing in vivo models and cell-based assays - Mimicking the human biology by humanizing the tumor microenvironment in mice - Studying the microbiota in cancer patients Oncology, Cancer research, Patient derived Xenograft, Cell lines, Ex vivo assays, Microbiota, Data mining , Translationnal medecine, Humanized mice, Biomarker, Research and Development, In vivo models, Ex vivo models, and Cancer 169 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | N/A |
 | LXRepair 2013-2023 2013-2023 In a context where the rate of cancer treatment failure is still unacceptably high, our mission is to provide decision aids to oncologists. We believe that profiling is key to predicting treatment toxicity to patients and effectiveness on tumors. Over a decade of research by the French Atomic Energy Commission (CEA) on the impact of radiations on DNA has resulted in a deep understanding of the essential DNA repair mechanisms. More recently, a set of innovative biomarkers was developed that provides a complete functional signature of these mechanisms, the premise to powerful tools for personalized treatment of cancer. http://www.lxrepair.com … 63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 3 |